Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shang-Yi, Lin, Hsiu-Hsia, Lin, Chung-Wu, Li, Chi-Cheng, Yao, Ming, Tang, Jih-Luh, Hou, Hsin-An, Tsay, Woei, Chou, Sheng-Je, Cheng, Chieh-Lung, Tien, Hwei-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308741/
https://www.ncbi.nlm.nih.gov/pubmed/27566569
http://dx.doi.org/10.18632/oncotarget.11519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308741/
https://www.ncbi.nlm.nih.gov/pubmed/27566569
http://dx.doi.org/10.18632/oncotarget.11519

Ejemplares similares